Arthrex grabbed headlines, but will it actually be a useful tool for PTAB oversight? Will the USPTO Director be willing to take a hard look at PTAB decisions? And what can we expect from a new Director? Winston & Strawn Attorneys Nimalka Wickramasekera and Juan Yaquian recently addressed this topic.
Listen to the episode here.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.